AHS 2022 | Differences and similarities between PROMISE-1 & PROMISE-2

Rami Apelian, MD, MPH, FAES, Huntington Headache and Neurology, Arcadia, CA, compares the PROMISE-1 (NCT02559895) and PROMISE-2 (NCT02974153) trials of eptinezumab. The setup for the clinical trials was very similar; the establishment of baseline headache frequency, drug and placebo administration, and primary endpoints were all the same. The study design was identical in this respect. However, the major differences between the two studies were the number of medication-use days and the migraine days the patient suffered. This interview took place during the 2022 American Headache Society (AHS) Meeting in Denver, CO.